PharmaTher Holdings Ltd (TSE:PHRM)
:PHRM
Top Page
PharmaTher Holdings Ltd
(PHRM)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.06
▼(-38.00% Downside)
Action:ReiteratedDate:03/11/26
The score is primarily pressured by weak financial fundamentals (pre-revenue operations, ongoing losses, negative cash flow, and eroding equity) despite improving burn rate and zero reported debt. Technicals also weigh on the score as the stock remains in a broader downtrend. Valuation is limited by negative earnings and no dividend support.
Positive Factors
Narrowing losses and improved cash burn
PHRM has materially narrowed net losses and slowed cash burn versus prior years, which is a durable operational improvement. Lower ongoing losses extend runway, reduce near-term financing pressure and signal tighter cost discipline important for pre-revenue biotech prioritizing R&D milestones.
Negative Factors
Pre-revenue business model
The company remains entirely pre-revenue, leaving future cash flow dependent on successful clinical outcomes or external funding. Without commercialization, the timing and probability of sustainable revenues are uncertain, making long-term viability contingent on development milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing losses and improved cash burn
PHRM has materially narrowed net losses and slowed cash burn versus prior years, which is a durable operational improvement. Lower ongoing losses extend runway, reduce near-term financing pressure and signal tighter cost discipline important for pre-revenue biotech prioritizing R&D milestones.
Read all positive factors
PharmaTher Holdings Ltd (PHRM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.92M
Dividend YieldN/A
Average Volume (3M)158.34K
Price to Earnings (P/E)―
Beta (1Y)-0.01
Revenue GrowthN/A
EPS Growth27.35%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume117,358
30 Day Avg. Volume158,340
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)16.46
Price to Sales (P/S)0.00
P/FCF Ratio-13.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmaTher Holdings Ltd Business Overview & Revenue Model
Company Description
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain ...
How the Company Makes Money
null...
PharmaTher Holdings Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -711.00 | -1.42K | -1.78K | -355.00 |
| EBITDA | -1.52M | -3.04M | -3.96M | -3.96M | -2.43M |
| Net Income | -1.53M | -3.12M | -6.42M | -4.01M | 2.66M |
Balance Sheet | |||||
| Total Assets | 1.34M | 2.59M | 6.31M | 12.16M | 5.94M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 2.30M | 6.25M | 12.12M | 5.88M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 366.33K | 252.90K | 892.48K | 330.32K | 361.06K |
| Stockholders Equity | 973.54K | 2.34M | 5.42M | 11.83M | 5.58M |
Cash Flow | |||||
| Free Cash Flow | -1.21M | -3.52M | -3.24M | -3.51M | 917.92K |
| Operating Cash Flow | -1.21M | -3.52M | -3.24M | -3.51M | 922.19K |
| Investing Cash Flow | 0.00 | -300.00K | 0.00 | 0.00 | 214.77K |
| Financing Cash Flow | 0.00 | 35.00K | 0.00 | 9.89M | 1.25M |
PharmaTher Holdings Ltd Technical Analysis
Negative
0.10
Price Trends
0.08
Negative
0.10
Negative
0.22
Negative
Market Momentum
>-0.01
Positive
41.96
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRM, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.96 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRM.
PharmaTher Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$9.87M | -6.03 | 19.14% | ― | ― | 62.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$7.83M | -6.62 | 64.41% | ― | ― | ― | |
42 Neutral | C$5.92M | -10.53 | -112.32% | ― | ― | 27.35% | |
41 Neutral | C$5.46M | -3.10 | ― | ― | ― | ― | |
| ― | C$1.75M | -1.60 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:PHRM
PharmaTher Holdings Ltd
0.07
-0.13
-65.79%
TSE:CSCI
COSCIENS Biopharma
2.83
-1.18
-29.43%
TSE:KNE
Kane Biotech
0.03
-0.07
-70.00%
TSE:BETR
BetterLife Pharma
0.07
-0.02
-23.53%
TSE:BIOV
BioVaxys Technology
0.06
-0.44
-88.00%
TSE:MRVL
Marvel Biosciences Corp
0.14
0.01
8.00%
PharmaTher Holdings Ltd Corporate Events
Business Operations and StrategyProduct-Related Announcements
PharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
Positive
Mar 26, 2026
PharmaTher Holdings has introduced PatchPrint, an automated tabletop 3D printer for microneedle patches, and filed a provisional U.S. patent for the system. The company aims to evolve from a product-focused developer into a broader microneedle pat...
Business Operations and StrategyProduct-Related Announcements
PharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform
Positive
Mar 3, 2026
PharmaTher Holdings Ltd is a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides. It develops its proprietary PharmaPatch microneedle patch platform to deliver drugs in a needle-free, at-hom...
Business Operations and StrategyProduct-Related Announcements
PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
Positive
Feb 2, 2026
PharmaTher Holdings Ltd. has launched a strategic initiative to seek Health Canada approval and subsequent commercialization of a generic version of semaglutide, the active ingredient in blockbuster diabetes and obesity drugs Ozempic and Wegovy, t...
Business Operations and StrategyProduct-Related Announcements
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
Positive
Jan 14, 2026
PharmaTher Holdings Ltd. announced a strategic expansion of its PharmaPatch microneedle patch platform into GLP-1 therapies aimed at treating obesity, building on preclinical progress and design know-how from its ketamine and psychedelic patch pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.